Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

After discount row, NICE finally says yes to first line Revlimid

After discount row, NICE finally says yes to first line Revlimid In a second piece of final draft guidance published today, NICE has also recommended Revlimid as a second line therapy with dexamethasone. ... However time is running out for Revlimid’s patent in Europe, which is due to expire in 2022, and could face

Orphan drugs market to soar to $224bn by 2024

Orphan drugs market to soar to $224bn by 2024 The report also revealed other interesting developments, including Celgene toppling Novartis as the world’s biggest orphan drug developer as its multiple myeloma therapy Revlimid is predicted to be the leading ... Revlimid generated sales of $2.6bn in

Post-merger Celgene to lead pharma growth

Post-merger Celgene to lead pharma growth Moody’s attributes Celgene's bright prospects to it strong late-stage pipeline, and continued growth from its blood cancer blockbuster Revlimid, despite fears of patent challenges to the drug, which ... The forecast has come ahead of Celgene’s Q1

BMS closes on Celgene merger after rebel investors bow out

BMS closes on Celgene merger after rebel investors bow out News on Revlimid patent also positive. Bristol-Myers Squibb chalked up a morale-boosting victory in its bid to close its $74bn merger with Celgene, after a rebel investment group abandoned ... Both shareholders have said they are concerned about

Celgene hopes for second time lucky for ozanimod FDA filing

Celgene hopes for second time lucky for ozanimod FDA filing One of six key drugs for BMS-Celgene merger

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics